Argenx reports Phase 3 efgartigimod benefit in autoimmune myositis

Argenx reported on August 17 that subcutaneous efgartigimod met the primary endpoint in the Phase 3 portion of ALKIVIA, a randomized trial involving adults with autoimmune myositis. The company said participants with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis improved more over 52 weeks than those receiving placebo alongside background therapy.

The result matters because autoimmune myositis can cause progressive muscle weakness, impaired daily function and damage beyond skeletal muscle. Treatment commonly relies on corticosteroids and other broad immunosuppressants. IMNM, the more treatment-resistant subtype highlighted in the announcement, has no specifically approved therapy in the United States.

What the trial tested

ALKIVIA was an operationally seamless Phase 2/3 study registered as NCT05523167. It enrolled adults with active idiopathic inflammatory myopathy, including dermatomyositis, IMNM and selected polymyositis subtypes. Participants were randomly assigned, under double-blind conditions, to weekly efgartigimod PH20 injections or matched placebo in addition to permitted background treatment.

The sponsor reported 264 participants across the complete study, including 175 in the Phase 3 portion. The Phase 3 protocol included a mandated corticosteroid taper. Its primary endpoint was the mean Total Improvement Score at week 52. This 0-to-100 composite incorporates six core measures covering muscle strength, physical function, patient and physician assessments, muscle-enzyme levels and disease activity outside the muscles; higher scores indicate greater improvement.

In the combined IMNM and dermatomyositis analysis, the mean score was 47.95 with efgartigimod and 32.56 with placebo, a 15.4-point difference favoring treatment. The reported p-value was 0.0011. Argenx said separation from placebo appeared by week four and continued through week 52 despite corticosteroid tapering.

Subgroup findings require care

The prespecified IMNM analysis also met its endpoint. Mean scores were 45.05 with efgartigimod and 30.24 with placebo, a 14.8-point difference, with a reported p-value of 0.0048.

Dermatomyositis showed a numerically similar 14.5-point difference: 51.51 versus 36.96. That subgroup result did not reach statistical significance, however, with a p-value of 0.1093. The company attributed this partly to the smaller cohort, but it did not disclose subgroup sample sizes in the topline release. The appropriate conclusion is therefore that the combined population and IMNM analysis were positive, while efficacy in dermatomyositis remains less certain.

Argenx also said all six components of the composite favored efgartigimod and that dermatomyositis skin activity improved. Component-level estimates were not released, so the relative contributions of muscle strength, function and more subjective assessments cannot yet be evaluated independently.

How efgartigimod is intended to work

Efgartigimod is an engineered human IgG1 antibody fragment that blocks the neonatal Fc receptor, or FcRn. FcRn normally protects IgG antibodies from degradation. Blocking it lowers circulating IgG, including pathogenic autoantibodies believed to contribute to muscle injury in some forms of myositis.

The drug is already approved in other autoimmune neuromuscular conditions, but the ALKIVIA result does not constitute regulatory approval for myositis. It also does not prove that every clinical feature or myositis subtype responds through the same mechanism.

What remains unanswered

The announcement contains no detailed adverse-event table, discontinuation rates, serious-infection data or laboratory findings. Argenx described tolerability as consistent with the established efgartigimod profile, but that general statement cannot substitute for complete safety results. Lowering IgG makes infection-related outcomes and longer-term immune effects particularly important to examine.

Full results have not been published in a peer-reviewed journal or posted to ClinicalTrials.gov. The registry still lists no summary results, and the company says detailed findings will be presented at a future medical meeting. Until those data are available, the trial offers a credible late-stage efficacy signal—strongest for the combined analysis and IMNM—but not a complete assessment of benefit, safety, durability or regulatory readiness.